Incyte Corp.

+0.66 (+0.78%)
Products, Regulatory, Other Pre-Announcement

Lilly And Incyte Communicate Review Extension Of Supplemental NDA For Baricitinib

Published: 04/06/2021 20:51 GMT
Incyte Corp. (INCY) - Lilly and Incyte Communicate Review Extension of Supplemental New Drug Application for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis.
Incyte Corp - Prescription Drug User Fee Act (pdufa) Action Date Has Been Extended Three Months to Early Q3 2021.
Incyte Corp - FDA Extended Action Date to Allow Time to Review Additional Data Analyses Submitted by Lilly in Response to Recent Information Requests.
Incyte Corp - Extension Does Not Affect Lilly's Previously-issued Financial Guidance for 2021.